Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 244Lung Neoplasms 77Melanoma 57Carcinoma, Renal Cell 44Small Cell Lung Carcinoma 33Colorectal Neoplasms 28Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Transitional Cell 24Neoplasms 23Triple Negative Breast Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 19Ovarian Neoplasms 17Mesothelioma 17Pancreatic Neoplasms 15Mesothelioma, Malignant 15Stomach Neoplasms 13Breast Neoplasms 13Uterine Cervical Neoplasms 12Urinary Bladder Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Merkel Cell 10Kidney Neoplasms 9Adenocarcinoma of Lung 8Esophageal Neoplasms 7Endometrial Neoplasms 7Lymphoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Prostatic Neoplasms 5

Interventions

fludarabine 2aldesleukin 2Cyclophosphamide 2fludarabine phosphate 1figitumumab 1Paclitaxel 1Nivolumab 1Interleukin-2 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Adenosquamous × Nivolumab × Thoracic × Clear all
NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
20 enrolled 10 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡